GNH USA

Europe — EMA

Orgalutran (Ganirelix)

GNH USA supplies Orgalutran (Ganirelix), a GnRH antagonist for controlled ovarian hyperstimulation in IVF and assisted reproductive technology.

Ganirelix

Request sourcing

1
Pack/s

What is Ganirelix?

Ganirelix, the active ingredient in Orgalutran, is a GnRH antagonist presented as an injection solution for subcutaneous use. It is employed to prevent premature luteinizing hormone surges and to regulate ovarian follicular development during controlled ovarian hyperstimulation for women undergoing in vitro fertilization (IVF) and other assisted reproductive technology procedures.

GNH USA supplies Orgalutran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide, ensuring quality and regulatory compliance across EU and global markets through rigorous testing and validated cold‑chain logistics.

What is Ganirelix used for?

Ganirelix, a GnRH antagonist, is used in assisted reproductive technology to manage ovarian response.

- Controlled ovarian hyperstimulation for IVF: suppresses premature LH surge to allow coordinated follicle development. - Assisted reproductive technology cycles: provides precise control of ovarian response during egg retrieval protocols. - Ovarian stimulation for egg collection: enables timing of ovulation trigger in fertility treatment cycles.

What are the side effects of Ganirelix?

Ganirelix may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the subcutaneous injection site. - Headache: transient mild to moderate headache. - Nausea or abdominal discomfort: occasional gastrointestinal upset. - Hot flashes: brief episodes of warmth and sweating.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): severe ovarian enlargement and fluid shift. - Severe allergic reaction: anaphylaxis, rash, or angioedema. - Thromboembolic events: rare clot formation. - Severe abdominal pain: may indicate ovarian torsion or rupture. - Elevated liver enzymes: rare hepatic involvement.

What precautions apply to Ganirelix?

When using Orgalutran, clinicians should observe several safety measures.

- Patient selection: assess ovarian reserve and baseline hormone levels before initiating therapy. - Monitoring: perform regular ultrasound and serum estradiol assessments to detect excessive response. - Concomitant medications: avoid use with other GnRH agonists or antagonists without specialist guidance. - Pregnancy considerations: discontinue before confirmed pregnancy; safety in pregnancy not established. - Allergy: screen for hypersensitivity to ganirelix or formulation components. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Ganirelix interact with?

Ganirelix can interact with other medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Concurrent GnRH agonists: may counteract the antagonist effect. - High‑dose estrogen therapy: may reduce ganirelix efficacy. - Other fertility drugs that strongly stimulate ovaries: increase risk of OHSS.

Moderate Interactions (Monitor Closely): - CYP450 substrates: monitor as ganirelix may affect metabolism of certain drugs. - Anticoagulants: observe clotting parameters due to potential vascular effects. - Vaccines: schedule appropriately to avoid overlapping immune responses.

Frequently asked questions

What is Orgalutran used for?+
Orgalutran contains ganirelix, a GnRH antagonist used to prevent premature luteinizing hormone surges during controlled ovarian hyperstimulation. It enables precise timing of ovulation in in‑vitro fertilisation (IVF) cycles and other assisted reproductive technology procedures.
How does ganirelix work?+
Ganirelix competitively blocks GnRH receptors in the pituitary gland, inhibiting the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). This suppression stops the natural LH surge, allowing clinicians to control follicle development and schedule ovulation triggers in fertility treatments.
What is the usual dose of Orgalutran?+
The dose of Orgalutran is individualized. A prescribing physician determines the amount, timing, and duration based on the patient’s ovarian response, treatment protocol, and monitoring results. Specific dosing regimens are not disclosed publicly.
Is Orgalutran safe during pregnancy or breastfeeding?+
Safety of ganirelix in pregnancy has not been established, and the product is generally discontinued before a confirmed pregnancy. Limited data exist for breastfeeding; therefore, use is not recommended without professional guidance.
How do I order Orgalutran from GNH USA?+
To order Orgalutran, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.
How does Orgalutran compare with the main alternative drug or class?+
Orgalutran (ganirelix) and other GnRH antagonists such as cetrorelix share the same mechanism of blocking GnRH receptors. Both provide rapid LH suppression, but differences may exist in dosing schedules, formulation, and manufacturer‑specific excipients. Choice often depends on protocol preference, availability, and clinician experience.
How should Orgalutran be stored and handled?+
Orgalutran must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.
How is Orgalutran administered?+
Orgalutran is given as a subcutaneous injection, typically into the abdominal wall or thigh. The injection is performed by a trained healthcare professional according to the timing outlined in the patient’s IVF protocol, often once daily during the stimulation phase.
What are the most serious risks to watch for with Orgalutran?+
Serious risks include ovarian hyperstimulation syndrome (OHSS), severe allergic reactions such as anaphylaxis, thromboembolic events, and rare hepatic disturbances. Patients should be monitored closely for abdominal pain, rapid weight gain, shortness of breath, or signs of an allergic response.
Who should not use Orgalutran?+
Orgalutran is contraindicated in individuals with known hypersensitivity to ganirelix or any formulation component. It should also be avoided in women who are already pregnant, and caution is advised for patients with severe liver disease or uncontrolled endocrine disorders.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Ganirelix
Route
Subcutaneous Use
Manufacturer
N.V. Organon
Origin
EU

Related products

Astarté

Astarté

Ganirelix

Gp-Pharm S.A.
EU
Astarté

Astarté

Ganirelix

Gp-Pharm S.A.
EU
Fyremadel

Fyremadel

Ganirelix

Sun Pharmaceutical Industries Europe B.V.
EU
Fyremadel

Fyremadel

Ganirelix

Sun Pharmaceutical Industries Europe B.V.
EU